Alveolar Ridge Sequelae Due to Peri-implantitis: a Retrospective Observational Study

November 11, 2021 updated by: Ramón Pons Calabuig, Universitat Internacional de Catalunya

"Dimensional Hard Tissue Changes Resulted at Removed Peri-implantitis Implant Sites: A Retrospective Study".

The scientific evidence available at present regarding the alterations suffered by the alveolar ridge after the explantation of implants that have been considered to be abandoned due to periimplantitis, as well as the remaining sequelae from said treatment, is scarce and inconclusive.

Regarding this background, it is speculated that the different types of peri-implant defects present different bone remodeling and different sequelae after the explantation of the implants affected by peri-implantitis.

Thus, it has been hypothesized that the peri-implant defect configuration has an influence on the radiographic bone alterations that occur after explantation.

In order to test this hypothesis, a retrospective study has been designed as it follows: Patients who have undergone implant placement procedure and suffer from peri-implantitis will be consecutively included in the study. In addition, patients should present at least 2 CBCTs taken before and after explantation, 4-6 months apart. Linear measurements will be taken in order to assess dimensional changes of the alveolar ridge at 1, 3, 5 and 7 mm from the bone crest.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Peri-implant diseases have been a growing problem for the last decades. A recent cross-sectional study conducted in the Spanish population has shown a prevalence of mucositis and peri-implantitis at the implant level of 27% and 20%, and of 27% and 18% at the patient level, respectively (Rodrigo et al. 2018). As the peri-implant disease progresses, it has been observed that it generates different types of defects around implants affected by this pathology. Recently, Monje et al. 2019, have classified these defects according to their morphology (infrabony defects, supracrestal/horizontal defects or combined defects) and according to the depth of the defect and total bone loss/total implant length (3-4mm/<25% of implant length, 4-5mm/≥25-50% of implant length, >6mm/>50% of implant length (Monje et al. 2019).

Bone remodeling, as well as the sequelae or morphological alterations suffered by the alveolar ridge after tooth extraction have been widely described in the literature (Amler et al. 1960, Evian et al. 1982, Cardaropoli et al. 2003). In an animal model, Araujo and coworkers described the alterations of the alveolar ridge following tooth extraction; observing that bone height reduction of the buccal plate was more pronounced than the lingual, and that vertical bone loss was always associated with horizontal bone loss (Araujo et al. 2005). In contrast, the evidence available nowadays regarding the alterations suffered by the alveolar ridge after the explantation of implants that have been considered to be removed due to peri-implantitis, as well as the remaining sequelae from said treatment, is scarce and inconclusive.

Therefore, the the primary objective of this study will be to evaluate radiographically the influence of the peri-implant defect configuration on the radiographic bone alterations after implant explanation.

In this sense, a retrospective observational study will be design. The protocol of which will be approved by the Ethics Committee of the University of Extremadura (Badajoz, Spain), and will follow the Declaration of Helsinki on human studies. In addition, this study will be reported in accordance with the Analysis Strenghtening the Reporting of Observational Studies in Epidemiology (STROBE) Statement .

Patient recruitment will be obtained from a private practice exclusively dedicated to periodontics and implantology. Edentulous patients, either total or partial, who previously underwent implant placement procedure will be consecutively included in the study. A prerequisite for being eligible for the study was to have at least 2 CBCts, one taken before explantation in order to diagnose peri-implantitis; and the other taken after explantation.

In order to define a peri-implantitis case, it will be based on the consensus report of Workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-implant Diseases and Conditions (Berglundh et al., 2018), in which it was stated that, in the absence of baseline information, the diagnosis of peri-implantitis required: presence of bleeding and/or suppuration on gentle probing, probing depth ≥6 mm and bone level ≥3mm apical to the most coronal portion of the implant or at the rough-smooth interface in transmucosal implants.

Once defined, several variables will be recorded, including both patient- and implant-related ones. The former will include age, gender, type of edentulism (total/partial), history of periodontal disease (mild, moderate or severe), tobacco smoking (heavy smoker >10 cigarettes/day; light smoker <10 cigarettes/day, former smoker 0 cigarette/day or non-smoker), numbers of implant per patient, and keratinized mucosa (0, <2 or ≥2 mm). Implant-related variables will include position (mandible / maxilla / anterior / posterior), implant system (brand, diameter, length and type of connection), implant macrodesign (transmucosal/bone level), type of prosthesis (single/multiple; screw/cement-retained), as well as explantation method (trephine, tweezers, forceps or implant removal kit). In addition, whether regeneration was performed or not after explantation will be recorded, as well as the material used for it.

For the radiographic assessment, images were acquired by CBCT i-CAT Model 17-19 (Imaging Sciences International LLC, Hatfield, PA, USA). The imaging parameters were set at a width and depth of 16 × 13 mm, 120 kVp, 20.27 mAs, scan time 14.7 seconds, resolution 0.25 voxel and a field of view (FOV), which varied based on the scanned region. Defect morphology and severity were determined using the OnDemand3D software (Cybermed, Seoul, Korea) by one previously calibrated examiner.

Prior to the assessment of the different radiographic variables, two reference lines will be established: longitudinal axis of the implant and a perpendicular line to it tangent to a reference point (sinus floor in the maxilla and mandibular base in the mandible). Several parameters will be assessed before and after explantation in each implant, including: bone-to-implant contact (BIC) at 4 sites (mesial, distal, buccal, lingual), defined as the first contact between the bone and the implant surface, assessed from the most coronal part of the intraosseous component of the implant; bone plate thickness (BPT), assessed at buccal and lingual in mm. The reference point will be the bone crest and bone thickness will be recorded at 1, 3, 5 and 7 mm from the crest. In addition, ridge width (RW) will be also recorded at 1, 3, 5 and 7 mm from the bone crest. If there is any discrepancy between buccal and lingual bone crest, the most apical one will be chosen as the reference.

In order to assess changes in bone crest height, the distance between the most coronal point of the bone crest (buccal and lingual) and the reference line tangent to a fixed reference point was calculated in mm.

BPT and RW at 1, 3, 5 and 7 mm will be also assessed when the implant has been already explanted, recording the months that have passed from the explantation.

For the characterization of the peri-implantitis defects, the defect morphology and severity classification by Monje and coworkers will be followed (Monje et al. 2019):

  • Morphology:

    • Class I: Infraosseous defect. Class Ia: Buccal dehiscence. Class Ib: 2-3 walls defect. Class Ic: Circumferential defect.
    • Class II: Supracrestal/horizontal defect.
    • Class III: Combined defect. Class IIIa: Buccal dehiscence + horizontal bone loss. Class IIIb: 2-3 walls defect + horizontal bone loss. Class IIIc: Circumferential defect + horizontal bone loss.
  • Severity: based upon the defect depth from the implant neck and ratio of bone loss/total implant length

    • Grade S: Slight: 3-4 mm/<25% of the implant length
    • Grade M: Moderate 4-5 mm/ ≥25%-50% of the implant length
    • Grade A: Advanced: >6 mm/>50% of the implant length

Regarding the statistical analysis, the statistical package (SPSS 15.0, SPSS Inc., Chicago, IL, USA, STATISTICS, version 7.1StatSoft, Inc. will be used for this purpose. The Pearson correlation test will be applied for the assessment of confounding factors and Linear regression models based on generalized estimating equations (GEEs) will be used to analyze the differences in the mean values of the post-extraction bone changes during the 2 time phases. This model will consider the correlations of within-subject repeated measures.

Study Type

Observational

Enrollment (Actual)

26

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Barcelona
      • Sant Cugat Del Vallès, Barcelona, Spain, 08195
        • Universitat Internacional de Catalunya

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patient recruitment will be obtained from a private practice exclusively dedicated to periodontics and implantology (Clinica CICOM, Badajoz, Spain). Edentulous patients, either total or partial, who previously underwent implant placement procedure and which suffer severe peri-implantitis will be consecutively included in the study.

Description

Inclusion Criteria:

  • patients aged 18-80 years
  • patients with partial or complete edentulism with ≥1 missing teeth restored with implant-supported restorations
  • patients with implants which had been in function for a minimum of 36 months after final prosthesis delivery
  • patients presenting implant explantation due to peri-implantitis

Exclusion Criteria:

  • pregnancy or lactation patients
  • patients treated by zygomatic or pterygoid implants
  • patients under intake of medications known to modify bone metabolism
  • patients with uncontrolled systemic diseases (ie: diabetes mellitus)
  • patients with active periodontal disease that required treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
bone level changes
Time Frame: 4-6 months after implant explantation
bone level changes (mm) and peri-implant defect morphology alterations after implant explantation
4-6 months after implant explantation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Jose Nart, Universitat Internacional de Catalunya

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

August 15, 2020

Primary Completion (ACTUAL)

August 30, 2020

Study Completion (ACTUAL)

September 1, 2020

Study Registration Dates

First Submitted

August 26, 2020

First Submitted That Met QC Criteria

August 26, 2020

First Posted (ACTUAL)

September 1, 2020

Study Record Updates

Last Update Posted (ACTUAL)

November 19, 2021

Last Update Submitted That Met QC Criteria

November 11, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peri-Implantitis

Clinical Trials on CBCT measurements

3
Subscribe